180 LIFE SCIENCES CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.8 USD | +1.76% |
|
-1.10% | -55.63% |
| 25/03 | 180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 11/03 | 180 Life Sciences Corp. Announces Board Changes | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 2.14M 178M |
|---|---|---|---|---|---|
| Net income 2022 | -38M -3.17B | Net income 2023 | -19M -1.58B | EV / Sales 2022 | - |
| Net cash position 2022 | 5.63M 469M | Net cash position 2023 | 922K 76.85M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.17
x | P/E ratio 2023 |
-0.08
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 96.65% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.76% | ||
| 1 week | -1.10% | ||
| Current month | -22.75% | ||
| 1 month | -8.16% | ||
| 3 months | -58.74% | ||
| 6 months | -79.22% | ||
| Current year | -55.63% |
1 week
1.68
2.07
1 month
1.333.00
Current year
1.335.89
1 year
1.3327.93
3 years
1.334 465.00
5 years
1.334 957.21
10 years
1.334 957.21
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 72 | - | |
Jim Woody
CEO | Chief Executive Officer | 81 | - |
Ozan Pamir
DFI | Director of Finance/CFO | 33 | 01/18/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 76 | - | |
Jim Woody
CEO | Chief Executive Officer | 81 | - |
Blair Jordan
BRD | Director/Board Member | 55 | 28/02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.8 | +1.76% | 20,610 |
| 25/24/25 | 1.769 | -2.81% | 15,900 |
| 24/24/24 | 1.82 | -4.21% | 16,708 |
| 23/24/23 | 1.9 | +5.56% | 48,335 |
| 22/24/22 | 1.8 | -1.10% | 31,756 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotes
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.
| 1st Jan change | Capi. | |
|---|---|---|
| -55.63% | 1.53M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- KBLM Stock
